Latisse Faces Patent Challenge
The FDA said a company is challenging Allergan’s patent protection for the eyelash drug Latisse, looking to make a generic version. (Source: WSJ.com: Health)
More here:
Latisse Faces Patent Challenge
Latisse Faces Patent Challenge
The FDA said a company is challenging Allergan’s patent protection for the eyelash drug Latisse, looking to make a generic version.
Read the original post:
Latisse Faces Patent Challenge
Latisse Faces Patent Challenge
The FDA said a company is challenging Allergan’s patent protection for the eyelash drug Latisse, looking to make a generic version.
See the original post:
Latisse Faces Patent Challenge
FDA: Allergan’s Web Site Is Misleading
The FDA said the Web site of Allergan’s Latisse is misleading because it suggests the company’s eyelash thickener is more safe than proven.
Go here to read the rest:
FDA: Allergan’s Web Site Is Misleading
Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse — First and Only Treatment Approved by the FDA for Hypotrichosis of…
IRVINE, Calif.–(BUSINESS WIRE)–Dec 26, 2008 – Allergan, Inc.
Read the original:
Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse — First and Only Treatment Approved by the FDA for Hypotrichosis of…
FDA OKs 1st Eyelash Drug Latisse
Title: FDA OKs 1st Eyelash Drug LatisseCategory: Health NewsCreated: 12/29/2008Last Editorial Review: 12/29/2008 (Source: MedicineNet Eyesight General) MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network , and receive $5 free advertising.
Continue reading here:
FDA OKs 1st Eyelash Drug Latisse
Allergan Eyelash Enhancer Approved
Allergan received FDA approval to market Latisse, a beauty treatment that increases the length, thickness and darkness of eyelashes by using a drug the company developed to treat glaucoma.
See more here:
Allergan Eyelash Enhancer Approved
FDA Advisory Committee Unanimously Recommends Approval of Latisse (Bimatoprost Solution 0.03%) as a Treatment for Hypotrichosis of Eyelashes
IRVINE, Calif.–(BUSINESS WIRE)–Dec 5, 2008 – Allergan, Inc. today announced the U.S. Food and Drug Administration (FDA) Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) voted unanimously (9-0) to recommend that the FDA approve Latisse..
See the original post here:
FDA Advisory Committee Unanimously Recommends Approval of Latisse (Bimatoprost Solution 0.03%) as a Treatment for Hypotrichosis of Eyelashes
Epione Beverly Hills- Revolutionary New Sunblock Formula ‘Protects and Corrects’
- Epione Beverly Hills Helps Kick Off 2010 Teen Choice Awards’ Festivities with KIIS FM
- Beverly Hills Leader in Cosmetic Procedures Earns Allergan’s Highest Level of Recognition
- Dr. Simon Ourian to Offer Industry Expertise to Medicis
- The Cast of ‘Jersey Shore’ Learns Safe Tanning Tips and Secrets from Epione Beverly Hills
- Image is Everything: Three Aesthetic Treatments for Building Confidence and Looking and Feeling Your Best
- Why More Women are Choosing OptiLipo over Liposuction
- Say “Adios” to Acne Scars
- New Laser Treatment Offers Revolutionary Response to Aesthetic Procedure Candidates’ Number One Concern: Recovery Time
- Epione Reveals a “Bright” New Solution for Dull, Sun Damaged Skin